SEC Form 4 · accession 0001708138-17-000015
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
Aug 16, 2017
Accepted (ET)
Aug 18, 2017 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 16, 2017 | G | 84,613 | $0.00 | D | 329,543 | D | |
| Common Stock | Aug 16, 2017 | M | 153,969 | $21.92 | A | 483,512 | D | |
| Common Stock | Aug 16, 2017 | F | 7,159 | $471.41 | D | 476,353 | D | |
| Common Stock | Aug 16, 2017 | F | 75,406 | $471.41 | D | 400,947 | D | |
| Common StockF1 | Aug 16, 2017 | S | 10,986 | $470.17 | D | 389,961 | D | |
| Common StockF2 | Aug 17, 2017 | S | 1,305 | $470.00 | D | 388,656 | D | |
| Common StockF3 | Aug 18, 2017 | S | 2,900 | $470.15 | D | 385,756 | D | |
| Common Stock | Jul 3, 2017 | G | 422 | $0.00 | D | 150,285 | I | by CLAT |
| Common Stock | holding | — | — | — | 2,300 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 83,652 | I | by Spouse as Trustee | |
| Common StockF4 | holding | — | — | — | 1,203 | I | by trust for grandch |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $21.92 | Aug 16, 2017 | M | 153,969 | D | — | Dec 17, 2017 | Common Stock | 153,969 | 153,969 | D |
Explanation of responses
- F1Represents volume-weighted average price of sales of 10,986 shares of Company stock on August 16, 2017 at prices ranging from $470.00 to $470.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2017 at each separate price.
- F2Represents volume-weighted average price of sales of 1,305 shares of Company stock on August 17, 2017 at prices ranging from $470.00 to $470.03. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 17, 2017 at each separate price.
- F3Represents volume-weighted average price of sales of 2,900 shares of Company stock on August 18, 2017 at prices ranging from $470.00 to $470.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2017 at each separate price.
- F4By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- F5The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.